Intarcia Therapeutics’ GLP-1 agonist product candidate for type 2 diabetes now belongs to i2o Therapeutics, which will make the treatment’s case for approval at an upcoming FDA advisory committee meeting. The startup’s $46 million Series A financing is one of several recently announced funding rounds.
It's safe to say Ed Mathers has accrued some industry know-how after 35 years in the biopharma industry — 15 of which have been spent on the investor side. So what's his take on today's high potential therapeutic areas?
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Top-selling diabetes drug Januvia may get a run for its money: Boston-based Intarcia Therapeutics released Phase 3 results saying its implantable device is more effective in treating diabetes and obesity than Januvia.